Ecnoglutide low dosage

DRUG2 trials

Sponsors

Hangzhou Sciwind Biosciences Co., Ltd.

Conditions

T2DMType 2 Diabetes MellitusWeight Management

Phase 3

A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM

CompletedNCT05680129

Hangzhou Sciwind Biosciences Co., Ltd.T2DM, Type 2 Diabetes Mellitus

Start: 2023-01-10End: 2024-10-12Updated: 2025-05-08

A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity

CompletedNCT05813795

Hangzhou Sciwind Biosciences Co., Ltd.Weight Management

Start: 2023-04-05End: 2024-10-10Updated: 2025-04-30

Related Papers

Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial.

2025-08-221 citations

Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

2025-06-213 citations